Lupin announced the launch of Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/mL) Multi-dose Vials, having received an approval from the
United States Food and Drug Administration (USFDA) earlier.
Lupin's Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme's Hectorol Inj ection, 4 mcg/2 ml (2 mcg/ml) Multi-dose Vials. It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis.
Doxercalciferollnjection, 4 mcg/2 ml (2 mcg/ml) Multi-dose Vials, (RLD: Hectorol) had an annual sales of approximately USD 132 million in the U.S. (IQVIA MAT October 2019).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
